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Mutations in MECP2, encoding the epigenetic regu-
lator methyl-CpG-binding protein 2, are the pre-
dominant cause of Rett syndrome, a disease
characterized by both neurological symptoms and
systemic abnormalities. Microglial dysfunction is
thought to contribute to disease pathogenesis, and
here we found microglia become activated and sub-
sequently lost with disease progression in Mecp2-
null mice. Mecp2 was found to be expressed in
peripheral macrophage and monocyte populations,
several of which also became depleted in Mecp2-
null mice. RNA-seq revealed increased expres-
sion of glucocorticoid- and hypoxia-induced tran-
scripts in Mecp2-deficient microglia and peritoneal
macrophages. Furthermore, Mecp2 was found to
regulate inflammatory gene transcription in response
to TNF stimulation. Postnatal re-expression of
Mecp2 using Cx3cr1creER increased the lifespan of
otherwise Mecp2-null mice. These data suggest
that Mecp2 regulates microglia and macrophage
responsiveness to environmental stimuli to promote
homeostasis. Dysfunction of tissue-resident macro-
phages might contribute to the systemic pathologies
observed in Rett syndrome.
INTRODUCTION
Rett syndrome, caused primarily by mutations in methyl-CpG
binding protein 2 (MeCP2) (Amir et al., 1999), features prominentneurologic sequelae (Chahrour and Zoghbi, 2007); accordingly,
efforts to understand the function of MeCP2 have been focused
largely on its role in neurons (Chahrour and Zoghbi, 2007).
Recent reports have found expression and roles for Mecp2 in
astrocytes (Ballas et al., 2009; Lioy et al., 2011; Yasui et al.,
2013), oligodendrocytes (Nguyen et al., 2013), and microglia
(Derecki et al., 2012; Maezawa and Jin, 2010). In addition,
Mecp2 is expressed in many tissues (Shahbazian et al., 2002).
Thus, mutations in MeCP2 likely affect multiple organ systems
and cell types, which is indeed reflected in the complexity of
symptoms associated with Rett syndrome (Chahrour and
Zoghbi, 2007; Dunn and MacLeod, 2001). While neurological
symptoms are prominent, most girls with Rett syndrome also
suffer from somatic impairments, including stunted growth,
osteopenia, scoliosis, and digestive difficulties (Chahrour and
Zoghbi, 2007; Dunn and MacLeod, 2001).
Many tissue-resident macrophages, including microglia, orig-
inate during embryonic hematopoiesis, beginning in the yolk sac
and moving to the fetal liver. These precursor cells disseminate
throughout tissues during embryogenesis, engraft within nearly
every organ system, and form self-renewing populations (Gin-
houx et al., 2010; Hashimoto et al., 2013; Kierdorf et al., 2013;
Schulz et al., 2012; Yona et al., 2013). Other populations of tis-
sue-resident macrophages, such as intestinal lamina propria in-
testinal macrophages, are constantly replenished by circulating
monocytes (Bain et al., 2013; Varol et al., 2009). The functional
roles of tissue-resident macrophages vary greatly and are
dependent upon location and context (Davies et al., 2013). How-
ever, all tissue-resident macrophages appear to be unified by
their role as provisioners of homeostatic maintenance (Davies
et al., 2013). Further, monocyte-derived inflammatory non-resi-
dent macrophages are critical for effective response to infection
and injury. In this context, these cells rely on a carefully balanced
network of skewing paradigms, which direct macrophageImmunity 42, 679–691, April 21, 2015 ª2015 Elsevier Inc. 679
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Figure 1. Microglia Become Activated and Subsequently Depleted with Disease Progression in Mecp2-Null Mice
(A) Flow cytometry demonstrating Mecp2 expression in microglia from whole brain.
(B) Cryosections from Cx3cr1GFP/+ wild-type mice demonstrating Mecp2 expression in microglia (scale bar represents 20 mm). Images were cropped from larger
images to allow for better visualization of Mecp2 localization within microglia.
(C) Representative stills from 2-photon live-imaging of late-phenotypic Cx3cr1GFP/+ wild-type and Cx3cr1GFP/+ Mecp2-null microglia.
(D) Quantitative assessment of microglial soma size measured by two-photon intravital microscopy in pre- and late-phenotypic Cx3cr1GFP/+ wild-type and
Cx3cr1GFP/+ Mecp2-null mice (*p < 0.05; **p < 0.01; two-way ANOVAwith Bonferroni post-test; for pre-phenotypic n = 44 wild-type and 54Mecp2-null microglia;
for late-phenotypic n = 51 wild-type and 40 Mecp2-null microglia. Microglia were measured from n = 3 mice per group. Error bars represent SEM).
(E) Sholl profiles for pre- and late-phenotypic wild-type and Mecp2-null microglia in hippocampus and neocortex showing intersections; (***p < 0.001; **p < 0.01;
*p < 0.05; two-way ANOVAwith Bonferroni post-test, n = 3mice per group with three separate areas from slices from identical brain structures analyzed per each
genotype. Data are presented as mean ± SEM).
(F and G) qRT-PCR of Tnf (F) and Tgfb1 (G) from pre- and late-phenotypic Mecp2-null mice and their age-matched wild-type controls (*p < 0.05; **p < 0.01; ***p <
0.001; two-way ANOVAwith Bonferroni post-test, n = 3mice for all groups except late-phenotypic wild-type for which n = 5. Data are presented asmean ± SEM).
(H) Flow cytometric analysis demonstrating the percentage ofmicroglia in whole brain preparations inMecp2-null micewith increasing disease severity. Numbers
show the percentage of Hoechst+ (nucleated) singlet CNS cells that are CD45loCD11b+ microglia.
(I) Quantification of microglia in pre- and late- phenotypic Mecp2-null mice as compared to age-matched wild-type controls. Cells were gated on Hoechst+
(nucleated cells), Singlets, Size, and CD45lo/neg to exclude peripheral immune cells. (Two-way ANOVA with Bonferroni post-test; pre-phenotypic, not significant.
Late-phenotypic; *p < 0.05. Pre-phenotypic versus late-phenotypic Mecp2-null; *p < 0.05. Overall main effect wild-type versus Mecp2-null; **p < 0.01. n = 7 pairs
(legend continued on next page)
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function including the initiation and resolution of inflammation,
clearance of debris and pathogens, and assistance in the healing
process (Sica and Mantovani, 2012). Notably, mice lacking
macrophage colony stimulating factor 1 receptor (CSF-1R) are
deficient in all macrophages and are characterized by multiple
organ failures and shortened lifespan (Dai et al., 2002), empha-
sizing the critical importance of macrophages in support of
bodily tissues.
Our previous work demonstrated that engraftment of wild-type
monocytes into the brains of Mecp2-null mice (through bone-
marrow transplantation) extends lifespan by several months and
improves neurologic and behavioral outcomes (Derecki et al.,
2012). In addition, phagocytosis of apoptotic cells in vitro is
impaired in Mecp2-null microglia. Although brain engraftment by
monocytes with bone-marrow transplant is crucial for significant
lifespan extension in Mecp2-null mice (Derecki et al., 2012), we
did not explore the possibility that Mecp2 might be important for
the normal function of other mononuclear phagocytes.
Here we demonstrated that numerous populations of macro-
phages and monocytes expressed Mecp2, and that Mecp2-
null mice become deficient in several macrophage populations,
including microglia. We next showed that postnatal re-expres-
sion of Mecp2 under a Cx3cr1-inducible promoter resulted in a
lifespan increase in otherwise Mecp2-null mice. In order to eluci-
date mechanisms behind themacrophage defects in the context
of Mecp2-deficiency, we demonstrated by RNA-Seq that
acutely isolated Mecp2-null microglia and peritoneal macro-
phages displayed changes in specific signaling pathways, sug-
gesting that Mecp2 is an important regulator of microglia and
macrophage gene expression. Further in vivo and in vitro valida-
tion studies confirmed that Mecp2 is important for proper tran-
scriptional regulation of multiple gene-expression programs in
macrophages. Overall, these results demonstrated that Mecp2
is an important epigenetic regulator of macrophage response
to stimuli and stressors.
RESULTS
Microglia Become Activated and Subsequently
Depleted with Disease Progression in Mecp2-Null Mice
Our previous data (Derecki et al., 2012) showing a role for micro-
glia in disease pathogenesis of Mecp2-deficient mice led us to
study in greater detail the role of Mecp2 in microglia and devel-
opmentally related peripheral tissue-resident macrophages.
Wild-type microglia were found to express Mecp2, as examined
by intracellular flow cytometric labeling (Figure 1A) or by in situ
immunofluorescence (Figure 1B). This is in line with previously
reported results (Maezawa and Jin, 2010).
We next investigated how loss of Mecp2 affects microglia
in vivo. Using a thinned-skull technique, we performed intravital
two-photon imaging on pre- and late-phenotypic Mecp2-null
and wild-type mice. We observed that pre-phenotypic Mecp2-
null microglia had significantly smaller somas (similar to
Mecp2-null neurons and astrocytes), whereas late-phenotypicof wild-type and Mecp2-null mice pooled from 3 independent experiments for pr
from four independent experiments for late-phenotypic groups. Error bars repre
(J) Brain region-specific microglia percentages as measured by flow cytomet
(*p < 0.05; **p < 0.01; ***p < 0.001; two-way ANOVA; n = 6 mice per group. ErroMecp2-null microglia soma were larger in size as compared to
wild-type (Figures 1C and 1D; Movies S1 and S2), suggestive
of microglia activation (Kozlowski and Weimer, 2012). In addi-
tion, in situ Sholl analysis demonstrated that while pre-pheno-
typic Mecp2-null microglia were not different from wild-type,
microglia from late-phenotypic mice displayed significantly
reduced process complexity in three examined brain areas (hip-
pocampus, neocortex, and cerebellum; Figure 1E). Together, the
findings of increased soma size and decreased process
complexity suggested that Mecp2-null microglia became acti-
vatedwith disease progression. Indeed, qRT-PCR of acutely iso-
lated Mecp2-null microglia from pre- and late-phenotypic mice
showed increased Tnf mRNA encoding the pro-inflammatory
cytokine tumor necrosis factor (TNF) (Figure 1F) while Tgfb1 tran-
scription, required for microglia maintenance (Butovsky et al.,
2014), was decreased in late-phenotypic microglia (Figure 1G).
We next examined Mecp2-null microglia by flow cytometry,
which revealed a progressive loss of microglia in Mecp2-null
mice from pre- to late-phenotypic stage (Figures 1H and 1I).
Loss of microglia was found throughout the brain (Figure 1J).
The loss was also observed in brains of late-phenotypic
Mecp2-null mice by immunohistochemistry (Figures S1A and
S1B). Further, immunohistochemical staining for Iba1, a micro-
glial marker, and for cleaved caspase 3 (CC3), a marker of
apoptotic cells, revealed sporadic CC3+ microglia in late-pheno-
typicMecp2-null brains (Figure S1C). In sum, these data suggest
that in the context of Mecp2-deficiency, microglia become acti-
vated and are lost with disease progression.
Meningeal Macrophages Are Lost with Disease
Progression in Mecp2-Null Mice
Whenanalyzingmicrogliaby intravital two-photonmicroscopy,we
also observed significant morphologic disruption of Cx3cr1GFP/+
meningeal macrophages in vivo in late-phenotypic Mecp2-null
mice suggestive of reactive phenotype (Figure 2A). To assess
meningeal macrophages in further detail, we performed immuno-
fluorescent labeling of meninges from pre-, mid-, and late-pheno-
typicMecp2-null mice using antibodies against CD163 and F4/80.
A progressive loss of macrophages at the late-phenotypic state
was evident in Mecp2-null mice (Figures 2B and 2C).
Perivascular macrophages in the meninges are F4/80+
CD163+, whereas a separate meningeal macrophage population
is F4/80+CD163– (Davies et al., 2013). When we analyzed
these populations separately, we found that perivascular macro-
phages (F4/80+CD163+) were progressively lost in Mecp2-
null mice (Figure 2D), whereas non-perivascular meningeal
macrophages (F4/80+CD163–) were not significantly depleted
(Figure 2E).
Peripheral Monocytes and Macrophages Express
Mecp2, and Some Are Lost in Mecp2-Null Mice
Given the phenotype of meningeal macrophages and microglia,
we decided to expand our analysis to additional populations of
peripheral macrophages. Many tissue-resident macrophages,e-phenotypic groups and n = 6 pairs of wild-type and Mecp2-null mice pooled
sent SEM).
ry in late-phenotypic Mecp2-null mice and age-matched wild-type controls
r bars represent SEM).
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Figure 2. Meningeal Macrophages Are
Lost with Disease Progression in Mecp2-
Null Mice
(A) Representative stills from intravital two-
photon microscopy of phenotypic Mecp2-null
meningeal macrophages demonstrating abnormal
morphology.
(B) Representative images of wild-type, mid and
late-phenotypic Mecp2-null meningeal macro-
phages. Upper panels, scale bar represents
200 mm. Lower panels, scale bar represents
100 mm.
(C) Quantification of total meningeal macrophages
in late-phenotypic Mecp2-null mice as compared
to wild-type, pre- and mid-phenotypic Mecp2-null
(one-way ANOVA with Bonferroni post-test; **p <
0.01. Error bars represent SEM).
(D) Quantification of F4/80+CD163+ perivascular
meningeal macrophages in late-phenotypic
Mecp2-null mice as compared to wild-type, pre
and mid-phenotypic Mecp2-null (one-way ANOVA
with Bonferroni post-test; *p < 0.01; **p < 0.01.
Error bars represent SEM).
(E) Quantification of F4/80+CD163– non-peri-
vascular meningeal macrophages in Mecp2-null
mice as compared to wild-type (one-way ANOVA
with Bonferroni post-test. Error bars represent
SEM).including microglia, originate from similar progenitor pools dur-
ing embryogenesis (Ginhoux et al., 2010; Hashimoto et al.,
2013; Kierdorf et al., 2013; Schulz et al., 2012; Yona et al.,
2013), and might therefore share pathologies in the context of
Mecp2-deficiency. We found that all tested tissue-resident mac-
rophages expressed Mecp2 (Figures 3A and 3B). In addition,
Ly6clo monocytes, which represent a longer-lived resident pop-
ulation in the blood (Yona et al., 2013) also expressed Mecp2
(Figure 3B). In contrast, Ly6chiCCR2+ monocytes and neutro-
phils expressed low or undetectable amounts of Mecp2
(Figure 3C).
As expected, based on the microglia and meningeal macro-
phage results described above, we found reductions of other
peripheral macrophage populations in Mecp2-null mice. Unlike
microglia, CD64+F4/80+CD11b+macrophages from the small in-
testine were reduced in both pre- and late-phenotypic Mecp2-
null mice (Figures 3D and 3E). Circulating Ly6clo monocytes
were also reduced in number in both pre- and late-phenotypic
Mecp2-null mice (Figures 3F and 3G).682 Immunity 42, 679–691, April 21, 2015 ª2015 Elsevier Inc.Because bothCD64+F4/80+CD11b+ in-
testinal macrophages and Ly6clo mono-
cytes share their derivation from Ly6chi
monocytes (Bain et al., 2013; Varol
et al., 2009; Yona et al., 2013), it is
possible that the reductions seen in these
populations even in pre-phenotypic
Mecp2-null mice might reflect their com-
mon origin. To this end, we tested
whether Ly6chi monocytes from bone
marrow were impaired in their ability to
differentiate and/or proliferate as macro-
phages in response to MCSF in vitro.We found that Mecp2-null Ly6chi monocytes differentiated into
macrophages with similar kinetics to wild-type and produced
similar numbers of macrophages per monocyte, making it an un-
likely possibility that Mecp2 is directly necessary for Ly6chi
monocyte differentiation or macrophage proliferation in the
absence of other factors (Figure S2).
Although Mecp2 did not affect differentiation or proliferation
in vitro, we hypothesized that Mecp2 might play a role in mono-
cyte/macrophage responses within the context of the full
disease caused by whole-animal Mecp2-deficiency. To test
this possibility, we depleted monocytes and macrophages using
intravenous (i.v.) clodronate liposomes in wild-type and Mecp2-
null littermates (mid-phenotypic, 6 weeks to allow for immune
system maturation but prior to the peak of disease) and
measured the repopulation of resident monocytes. DiI liposomes
were injected i.v. 2 days after clodronate liposome injection,
similar to published protocols (Sunderko¨tter et al., 2004). Ly6chi
monocytes released from the bone marrow become DiI labeled
and can be tracked in their differentiation to Ly6clo monocytes.
On day 5 post-clodronate injection (day 3 post DiI), wild-type and
Mecp2-null mice had, as expected, begun to reconstitute their
circulating monocyte populations, with a non-significant trend
toward fewer total monocytes (CD115+CD11b+) in Mecp2-null
mice (Figures 3H and 3I). However, when total monocytes
were examined, Mecp2-null mice had significantly fewer resi-
dent Ly6clo monocytes as compared to wild-type (Figure 3J).
In addition, when only DiI+ monocytes were examined (repre-
senting only the circulating monocytes present on day 2 post-
clodronate injection), DiI+ monocytes in wild-type mice had
almost completely differentiated into Ly6clo resident monocytes,
whereas Mecp2-null mice displayed a deficit in Ly6clo monocyte
differentiation (Figure 3K). The fact that some populations were
deficient in the pre-phenotypic state (resident monocytes and
intestinal macrophages), but others were lost progressively
(microglia and meningeal perivascular macrophages) led us to
hypothesize thatMecp2 is likely playing a complex role inmacro-
phage biology which is not limited to macrophage survival and/
or death. Of note, we did not observe any difference in F4/
80+CD163– meningeal macrophages (Figure 2E) or splenic red
pulp macrophages (data not shown), which also express
Mecp2 (Figures 3A and 3B), further suggesting that the role of
Mecp2 in macrophages is complex or upstream of cell loss
and/or death, because not all macrophage populations were
equally affected by Mecp2-deficiency. In addition, our data
regarding microglia suggested inflammatory activation (Figures
1C–1G), implicating Mecp2-deficiency in processes beyond
simple loss of microglia/macrophages. Overall, the data sug-
gested a complex role for Mecp2 in macrophages, consistent
with its previously described role in other cell types as an epige-
netic regulator, affecting a multitude of genes (Guy et al., 2011).
Postnatal Expression of Mecp2 via Cx3cr1creER in
Otherwise Mecp2-Deficient Mice Increases Lifespan
Previously we showed that transplantation of Mecp2-null mice
with wild-type bone marrow increases lifespan, and that engraft-
ment of microglia-like cells into the brain is important for this
effect (Derecki et al., 2012). More recently, Cx3cr1creER mice
have become available (Goldmann et al., 2013; Yona et al.,
2013), and microglia are among a subset of macrophages with
high expression of CX3CR1 during adulthood (Jung et al.,
2000). Thus the Cx3cr1creER mouse can be used to efficiently
target microglia, in addition to other CX3CR1-expressing mono-
cytes and macrophages. Therefore, we crossed Cx3cr1creER
mice with Mecp2Lox-stop mice and their offspring (Cx3cr1creER/+
Mecp2Lox-stop/y) were treated with tamoxifen (9 weeks of
age), when symptoms just started to appear. In line with our
previous finding with bone-marrow transplantation (Derecki
et al., 2012), the lifespan of tamoxifen-treated Cx3cr1creER/+
Mecp2Lox-stop/y mice was significantly extended (Figure 4A)
and weight loss was reversed as compared to oil-treated con-
trols (Figure 4B), supporting the importance of microglia and
macrophages in the arrest of pathology. In order to test for spec-
ificity of Mecp2 expression after tamoxifen treatment, we placed
Cx3cr1creER/+Mecp2Lox-stop/y mice on a tamoxifen diet for
3 months to maximize expression in any cells that would have
the potential to recombine. As expected, we found no significant
expression of Mecp2 in T or B cells, and partial re-expression in
monocytes (Figure 4C), as previously reported (Yona et al.,2013). In the spleen, we found a small percentage of Mecp2-ex-
pressing red pulp macrophages (20%) (Figure 4D), consistent
with the fact that red pulp macrophages do not express high
amounts of CX3CR1. However, CD64+F4/80+ intestinal macro-
phages and microglia, in which CX3CR1 is highly expressed,
had nearly 100% Mecp2 recombination (Figures 4E and 4F).
Non-microglia cells in the CNS displayed no Mecp2 recombina-
tion (Figure 4G). Together, these results support that Mecp2-
deficiency in microglia/macrophages contributes to pathology
and that restoring Mecp2-mediated regulation of transcriptional
responses has the potential to mediate benefits in the context of
whole-body Mecp2-deficiency.
Mecp2 Regulates Glucocorticoid and Hypoxia
Responses in Microglia and Peritoneal Macrophages
In order to define the functional role of Mecp2 in macrophages,
we examined the global gene-expression profile in microglia
and peritoneal macrophages derived from Mecp2-null mice.
We detected increased expression of glucocorticoid-induced
transcriptional signature genes in Mecp2-null cells when com-
pared to their wild-type counterparts, suggesting that Mecp2
functions as a repressor of this pathway (Figures 5A–5D and
Tables S1, S2, and S3). Among the dysregulated genes in
Mecp2-null microglia and peritoneal macrophages, Fkbp5, a
canonical glucocorticoid target gene, was strongly upregulated
(Figures 5A and 5C). A number of studies have demonstrated
that Mecp2 directly represses the Fkbp5 gene (Nuber et al.,
2005; Urdinguio et al., 2008). Using chromatin immunoprecipita-
tion (ChIP) analysis, we demonstrated Mecp2 binding to the
Fkbp5 gene promoter in bone marrow-derived macrophages
(BMDM) (Figure 5E). Furthermore, Mecp2 deletion resulted in
increased amounts of histone H4 acetylation at cis-regulatory re-
gions of Fkbp5 gene under basal conditions (Figure 5F). These
results suggest that Mecp2 restrains Fkbp5 gene expression
through epigenetic mechanisms. ChIP analysis demonstrated
the binding of nuclear receptor co-repressor 2 (Ncor2) and his-
tone deacetylase 3 (Hdac3) to the promoter region at the
Fkbp5 gene (Figure S3). These results are consistent with the
well-established role of Mecp2 in the recruitment of the Ncor2
and Hdac3 complex to target genes (Ebert et al., 2013; Lyst
et al., 2013). We next examined the Fkbp5 gene-expression pro-
file in dexamethasone-treated wild-type and Mecp2-null macro-
phages. Our results revealed that Mecp2 controls the sensitivity
of the Fkbp5 gene to glucocorticoid stimulation. Mecp2 deletion
resulted in the upregulation of Fkbp5 gene expression under
dexamethasone stimulation at a low dose normally incapable
of triggering Fkbp5 gene expression (Figure 5G).
We noticed that the glucocorticoid-induced gene set contains
a number of hypoxia-inducible genes (Table S3). Furthermore,
our gene set enrichment analysis demonstrated significantly
increased expression of a subset of hypoxia-inducible genes in
Mecp2-null microglia (Figures 5H and 5I). To validate the cell-
intrinsic role for Mecp2 in the negative regulation of these
hypoxia-inducible genes, we cultured BMDM under either nor-
moxia or hypoxia conditions (1% O2) and examined their
mRNA using quantitative PCR analysis. We validated in-
creased expression of three canonical hypoxia-inducible genes,
Hif3a, Ddit4, and Cyr61 in Mecp2-null macrophages cultured
under hypoxia conditions when compared to their wild-typeImmunity 42, 679–691, April 21, 2015 ª2015 Elsevier Inc. 683
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Figure 3. Peripheral Monocytes and Macrophages Express Mecp2, and Some Are Lost in Mecp2-Null Mice
(A) Example gating strategy for Mecp2 expression; shown are red pulp macrophages from spleen.
(B) Mecp2 expression in macrophage andmonocyte populations as measured by intracellular flow cytometric staining in wild-type andMecp2-null mice. Gating:
bone-marrow-resident macrophages- Size, CD45+, Singlets, Ly6c–, F4/80+, CD11blo, CD3–, SSClo; Splenic red pulp macrophages- CD45+, Singlets, F4/80+,
B220, Size, SSClo, Ly6g, Ly6c; Peritoneal resident macrophages- Size, Singlets, CD45+, CD11b+, F4/80hi; Intestinal macrophages- Singlets, viability, CD45+,
CD11b+, CD64+; Splenic Ly6clo monocytes, CD45+, Singlets, CD115+, SSClo, Ly6clo.
(legend continued on next page)
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B Figure 4. Postnatal Expression of Mecp2
via Cx3cr1creER in Otherwise Mecp2-Defi-
cient Mice Increases Lifespan
(A) Survival of Cx3cr1creER/+Mecp2Lox-stop/y mice
after postnatal tamoxifen or oil control treatment
in phenotypic mice (**p < 0.01; log-rank Mantel-
Cox test; tamoxifen treated n = 8, oil treated
n = 14).
(B) Weight change after postnatal tamoxifen or oil
control treatment in phenotypic Cx3cr1creER/+
Mecp2Lox-stop/y mice (**p < 0.01; ***p < 0.001.
Two-way ANOVA with Bonferroni post-test; n = 5
oil and n = 3 tamoxifen treated Cx3cr1creER/+
Mecp2Lox-stop/y. n = 7 Cx3cr1creER/+Mecp2+/y
tamoxifen treated. Asterisks over Cx3cr1creER/+
Mecp2Lox-stop/y oil-treated indicate comparisons
toCx3cr1creER/+Mecp2Lox-stop/y tamoxifen-treated.
Asterisks over Cx3cr1creER/+Mecp2Lox-stop/y
tamoxifen-treated indicate comparisons to
Cx3cr1creER/+Mecp2+/y. Data are presented as
mean ± SEM).
(C–G) Analysis of Mecp2 re-expression in tamox-
ifen treated mice. Mice were fed tamoxifen food
for 3 months to maximize possible recombina-
tion and analyzed by flow cytometry. Flow cy-
tometry plots displaying Mecp2 expression in
Cx3cr1creER/+Mecp2Lox-stop/y mice with or without
tamoxifen treatment in (C) circulating monocytes,
B, and T cells; (D) red pulp macrophages; (E) in-
testinal macrophages; (F) microglia; and (G) total
non-microglia nucleated cells in the CNS.counterparts (Figure 5J), confirming a role for Mecp2 in regula-
tion of at least a subset of hypoxia-induced gene transcripts.
Mecp2 Restrains Inflammatory Responses in
Macrophages
Our RNA-seq analysis revealed increased expression of Tnf
induced transcriptional signature genes in Mecp2-null microglia
cells when compared to their wild-type counterparts (Table S2).
These results indicate that Mecp2-deficiency leads to dysregu-(C) Flow cytometric Mecp2 staining in inflammatory monocytes (Ly6chiCCR2+
CD45+, Singlets, CD115+, SSClo, Ly6chi; Neutrophils- Singlets, CD45+, CD11b+,
(D and E) Flow cytometric analysis of resident intestinal macrophages in Mecp2-
plots showing the percentage of CD64+F4/80+ out of all CD45+ intestinal cells in
type controls. (E) Quantification of CD64+CD11b+ intestinal macrophages as me
Bonferroni post-test; **p < 0.01; ***p < 0.001) and absolute cell counts per anima
representative of two independent experiments for phenotypic mice. Data are p
(F) Flow cytometry plots of Ly6chiCCR2+ and Ly6clo blood monocytes in pre- a
controls. Numbers represent percentage of cells out of Singlets, Live, CD45+CD
(G) Quantification of numbers of circulating Ly6chiCCR2+ and Ly6clo monocytes (*p
group. Error bars represent SEM).
(H) Representative plots of CD11b+CD115+ total monocytes from blood of wild-t
(I) Monocyte count from peripheral blood of Mecp2-null and wild-type controls on
not significant. Error bars represent SEM).
(J) Representative flow cytometry plots displaying differentiation of Ly6chiCCR2+
monocytes on day 5 post clodronate liposome injection; representative of two ind
bars represent SEM).
(K) Same as (J), except only DiI+ monocytes are shown (cells labeled on day 2
dependent experiments. ***p < 0.001 (unpaired two-tailed Student’s t test. Errorlation of inflammatory responses in microglia and macrophages.
To validate this finding, we examined the role of Mecp2 in the
regulation of TNF-induced inflammatory responses in macro-
phages. We observed increased expression of Il6, Tnf, Cxcl2,
Cxcl3, and Csf3 genes in TNF-stimulated Mecp2-null BMDM
when compared to wild-type counterparts (Figure 6A). In order
to corroborate these findings in vivo, we examined the inflamma-
tory response of resident peritoneal macrophages. Mice were in-
jected intraperitoneally with TNF, allowed to respond for 6 hr,) and neutrophils (Ly6ghiCD11b+). Gating: Splenic Ly6chiCCR2+ monocytes-
Ly6g+.
null mice as compared to wild-type control. (D) Representative flow cytometry
pre- and late-phenotypic Mecp2-null mice as compared to age-matched wild-
asured by both percentage of total live intestinal cells (two-way ANOVA with
l (two-way ANOVA with Bonferroni post-test; **p < 0.01; ***p < 0.001). Data is
resented as mean ± SEM.
nd late-phenotypic Mecp2-null mice as compared to age-matched wild-type
11b+Ly6g–CD115+SSClo monocytes.
< 0.05; **p < 0.01; two-way ANOVAwith Bonferroni post-test; n = 6–8mice per
ype and Mecp2-null mice on day 5 post clodronate liposome injection.
day 5 post clodronate liposome injection (unpaired two-tailed Student’s t test,
monocytes to Ly6clo monocytes and quantification of %Ly6cloCCR2– resident
ependent experiments. (***p < 0.001, unpaired two-tailed Student’s t test. Error
post clodronate injection via DiI liposome injection); representative of two in-
bars represent SEM).
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and then peritoneal cells were collected by lavage. Cells from
peritoneal lavage were positively selected for F4/80+ macro-
phages via AutoMACS. Peritoneal macrophages from Mecp2-
null mice injected with TNF displayed an altered transcriptional
response as compared to wild-type (Figure 6B), including both
over- and under-expression of multiple TNF response genes.
No differences in baseline expression were evident in peritoneal
macrophages from mice after saline treatment (Figure S4). Tar-
gets observed in vitro with TNF stimulated BMDMs were also
overexpressed in peritoneal macrophages stimulated with TNF
in vivo, suggesting that Mecp2 has consistent transcriptional
roles across macrophage populations (Figures 6A and 6B).
Csf3, the gene encoding granulocyte-colony stimulating factor
(GCSF), was overexpressed in TNF-stimulated Mecp2-null
macrophages both in vitro and in vivo (Figures 6A and 6B).
Late-phenotypic Mecp2-null mice without any manipulation
also displayed increased GCSF protein in serum (Figure 6C).
Because a well-established effect of GCSF is to stimulate
neutrophil production (Bendall and Bradstock, 2014), we exam-
ined neutrophil numbers in Mecp2-null mice. Indeed, we found
that Mecp2-null mice develop severe neutrophilia (Figures S5A
and S5B). In addition, GCSF is known to drive the egress of he-
matopoietic stem cells (HSC) from the bonemarrow (Bendall and
Bradstock, 2014) and as expected, late-phenotypic Mecp2-null
mice also became progressively deficient in bone marrow HSC
with disease progression (Figures S5C and S5D). In order to
test whether or not neutrophilia and HSC loss play a role in the
disease, we treated Mecp2-null mice with a neutralizing anti-
GCSF antibody beginning at age 6–7 weeks (a mid-phenotypic
time-point). Flow cytometric analysis revealed rescue of neutro-
philia (Figure 6D) and prevention of HSC loss (Figure S5E). The
treatment also moderately increased the lifespan of Mecp2-null
mice (Figure 6E).
Together, these findings implicate Mecp2 in control of the
macrophage inflammatory response, which might have down-Figure 5. Mecp2 Regulates Glucocorticoid and Hypoxia Responses in
(A) Scatterplot comparing global gene-expression profiles between wild-type and
in gene-expression levels. Data represent the average of six wild-type and three M
mice and 9 mice respectively). mRNA expression is shown on a log2 scale.
(B) GSEA reveals the over-representation of glucocorticoid transcription signatu
tribution of the genes in the glucocorticoid transcription signature gene set (‘‘Hits
and three Mecp2-null samples.
(C) Scatterplot comparing global gene-expression profiles betweenwild-type and
pooled wild-type and six pooled Mecp2-null mice.
(D) Global gene expression in wild-type and Mecp2-null peritoneal macrophages
six pooled Mecp2-null mice.
(E) ChIP of Mecp2 from unstimulated wild-type macrophages showing binding of
(negative control). Data represent the average of three independent experiment
presented as mean ± SEM).
(F) ChIP analysis of histone H4 acetylation at the Fkbp5 gene promoter in wild-t
pendent experiments (***p < 0.001 and **p < 0.01; unpaired two-tailed Student’s
(G) Dexamethasone-stimulation of wild-type and Mecp2-null macrophages was
induction of Fkbp5 mRNA was significantly increased in Mecp2-null macrophage
and **p < 0.01; unpaired two-tailed Student’s t test. Data are presented as mean
(H) Scatterplot comparing global gene-expression profiles betweenwild-type and
in gene-expression levels. Data represent the average of six wild-type and threeM
mice respectively). mRNA expression levels are on a log2 scale.
(I) GSEA reveals the over-representation of hypoxia signature genes in unstimula
(J) Wild-type andMecp2-null macrophages were grown in hypoxia or normoxia fo
Results are representative of three independent experiments (average of three vstream implications for complex disease processes in the
context of Mecp2-deficiency.
DISCUSSION
In this work, we have demonstrated that Mecp2 is widely ex-
pressed across macrophage populations, and that Mecp2-
deficiency leads to transcriptional impairment and/or loss of
macrophages in multiple tissues. Postnatal genetic rescue of
several tissue-resident macrophage and monocyte populations
via Cx3cr1creER-mediated expression of Mecp2 resulted in
increased lifespan. We have further provided evidence that
Mecp2 is required for macrophage responses to multiple stimuli
through both RNA-Seq of acutely isolated Mecp2-null microglia
and peritoneal macrophages, and both in vitro and in vivo valida-
tion of pathways identified through RNA-seq. Together, these
findings implicate macrophages, and potentially monocytes, as
previously unrecognized players in Rett syndrome pathology.
Our results also suggest that Mecp2 is an important regulator
of macrophage response to stimuli/stressors, and future work
examining the mechanisms of transcriptional and epigenetic
regulation of macrophage responses should take into account
the role of Mecp2 in macrophage activation.
These findings support the notion that both malfunction and
loss of macrophages and resident monocytes might be a
contributing factor in Rett syndrome pathologies occurring
across multiple organ systems. Our finding that Mecp2-null
macrophages display impaired response to multiple stimuli—
including glucocorticoids, hypoxia, and inflammation—might
be of particular importance in the context of Mecp2-deficient
animals, as the level of general organ dysfunction is high com-
pared to wild-type mice; therefore, ongoing dysfunction of other
cell types, such as neurons, might increase the cellular stress
and/or activation upon Mecp2-null microglia and macrophages
and thereby exacerbate their loss and/or further pathologyMicroglia and Peritoneal Macrophages
Mecp2-null microglia. The black lines indicate a 2-fold cut-off for the difference
ecp2-null samples, with each sample representing three pooled mice (thus, 18
re genes in Mecp2-null microglia. The middle part of the plot shows the dis-
’’) against the ranked list of genes. Data represent the average of six wild-type
Mecp2-null peritoneal macrophages as in (A). Data represent the average of six
was analyzed as in (B). Data represent the average of six pooled wild-type and
Mecp2 to the promoter region of the Fkbp5 gene. Data were normalized to IgY
s. ***p < 0.001 and **p < 0.01, (unpaired two-tailed Student’s t test. Data are
ype and Mecp2-null macrophages. Data represent the average of three inde-
t test. Data are presented as mean ± SEM).
associated with a significant increase in Fkbp5 mRNA levels. Dexamethasone
s. Data represent the average of three independent experiments (***p < 0.001
± SEM).
Mecp2-null microglia. The black lines indicate a 2-fold cut-off for the difference
ecp2-null samples, with each sample representing three pooledmice (18 and 9
ted Mecp2-null microglia.
r 24 hr. mRNA levels ofHif3a,Ddit4, andCyr61weremeasured using qRT-PCR.
aluesc ± cSEM; ***p < 0.001 by unpaired two-tailed Student’s t test).
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Figure 6. Mecp2 Restrains Inflammatory Responses in Macrophages
(A) Wild-type and Mecp2-null macrophages were treated for 6 hr with TNF and subjected to quantitative real time PCR (qRT-PCR) for Tnf, Il6, Cxcl2,
Cxcl3, and Csf3. Data are representative of three experiments (average of three values ± SEM; ***p < 0.001 and **p < 0.01; Two-way ANOVA with Bonferroni
post-test).
(B) Mecp2-null or age-matched wild-type mice were injected with intraperitoneal TNF and allowed to respond for 6 hr. Resident peritoneal macrophages were
collected by lavage and subsequent AutoMACS sort for F4/80+ cells. RNA was collected and qRT-PCR performed for the indicated genes. One sample was
removed due to significantly lower purity of macrophages (50% vs 70%–80% for all other samples; the removed sample was an outlier as measured by >2 SD
below themean for macrophage purity). *p < 0.05; two-way ANOVAwith Bonferroni post-test. Interaction for Genotype and Gene; *p = 0.01. N = 3wild-type and 4
Mecp2-null. Data are presented as mean ± SEM.
(C) Granulocyte colony-stimulating factor (GCSF) ELISA of serum from late-phenotypic Mecp2-null mice and wild-type controls (*p < 0.05; Mann-Whitney two-
tailed; n = 9 per group. Data are presented as mean ± SEM).
(D) Representative flow cytometry plots of Mecp2-null and wild-type mice treated with anti-GCSF neutralizing or isotype antibodies showing percentage of
neutrophils out of all CD45+ circulating blood cells. Plots are representative of two independent experiments performed with n = 2 mice for all groups, analyzed
1–2 weeks post start of injections.
(E) Survival of Mecp2-null mice treated with either anti-GCSF neutralizing or isotype antibodies (*p < 0.05; log-rank Mantel-Cox test; n = 11 per group).
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induced by maladaptive responses to stimuli by Mecp2-null
macrophages. Such a positive feedback loop involving multiple
cell types and tissues could help explain the progressive devel-
opment of symptoms in Mecp2-null mice, which ultimately lead
to death. These results might also explain why cell-specific
deletion of Mecp2 in microglia cells did not result in significant
symptoms of Rett syndrome (unpublished data); Mecp2-null
microglia and macrophages represent amplifiers of pathology,
driven primarily by neurons, and thus their replacement by
wild-type cells abrogates the otherwise vicious cycle and slows
down the disease progression; however, without the pathology
driven by neurons (such as apneas, abnormal glucocorticoid
response, etc.), Mecp2-null microglia cannot induce a Rett-like
pathology.
It is well-recognized that girls suffering from Rett syndrome
experience severe problems outside the CNS, such as gastroin-
testinal distention, defects of nutrient absorption, scoliosis, os-
teopenia, and general somatic growth deficits (Chahrour and
Zoghbi, 2007; Dunn and MacLeod, 2001). Intestines contain a
large number of immune cells, including a significant fraction of
macrophages (Zigmond and Jung, 2013). Osteoclasts are key
players in bone turnover and homeostasis (Davies et al., 2013).
Thus, it is conceivable that pathology in both the gastrointestinal
tract and the bones could be exacerbated by defects of tissue-
resident macrophage function and/or loss of tissue-resident
macrophages in these tissues. It has been suggested that mac-
rophages might be one of the two largest sources of insulin-like
growth factor 1 (IGF-1), which is a critical growth factor involved
in growth and health of a multitude of tissues (Gow et al., 2010).
In addition, IGF-1 treatment has been shown to increase the
lifespan of Mecp2-null mice (Tropea et al., 2009) and recently
initiated clinical trials are promising (Khwaja et al., 2014). It is
therefore possible that functional defects and loss of tissue-resi-
dent macrophages in Mecp2-deficient mice, and possibly Rett
syndrome, might contribute to overall pathology via deficiency
of macrophage-derived IGF-1. Moreover, our RNA-seq data
shows that Mecp2-null microglia express increased amounts
of Igfbp3, a binding protein for IGF-1, which binds soluble
IGF-1 and neutralizes its function.
In recent groundbreaking work examining deletion of Mecp2
in adult mice, phenotypic progression is similar in time-scale
to that seen in mice null from birth (McGraw et al., 2011). This
might support the hypothesis that accumulation of cellular stress
in the absence of Mecp2 is progressively detrimental to cells
necessary for tissue homeostasis, such as tissue-resident
macrophages.
Beyond Rett syndrome, this work suggests that Mecp2 is an
epigenetic regulator of macrophages. Given the diversity and
plasticity of macrophages across organ systems, understanding
the role of Mecp2 in each specific macrophage population might
prove a difficult task. However, understanding the role of Mecp2
in macrophages, and the immune system as a whole, could lead
to greater understanding of several diseases in addition to Rett
syndrome, including MeCP2 duplication/triplication syndrome
(Chahrour and Zoghbi, 2007), and systemic lupus erythematosus
(Koelsch et al., 2013), which has been linked to abnormalities of
MeCP2 in humans.
We found genetic dysregulation in response to multiple stimu-
lations in Mecp2-null macrophages, which in vivo might actalone or in concert depending upon the exact conditions pre-
sented to the cell. For instance, many of the hypoxia-induced
transcripts measured to be abnormal in Mecp2-null macro-
phages, were also found in the disrupted glucocorticoid path-
ways identified by RNA-Seq. Therefore, such transcripts might
represent independent dysfunction in Mecp2-null macrophages
in the context of hypoxia alone, or an additional complication of
glucocorticoid-induced transcription depending on context.
Further, the combination of glucocorticoid stimulation and hyp-
oxia might result in complex transcriptional dysregulation.
Our validation studies of inflammatory-, hypoxia-, and gluco-
corticoid- signaling confirm a macrophage-intrinsic role for
Mecp2 in proper execution of these transcriptional responses.
We validated in vitro that stimulation of Mecp2-null macro-
phages demonstrates excessive and dysregulated inflammatory
response and excessive response to low-dose glucocorticoids,
which have been previously shown to contribute to pathology
in mouse models of Mecp2-deficiency (Braun et al., 2012). Of
particular note, we found that Mecp2-null mice develop an in-
flammatory activation of microglia with disease progression,
and that resident peritoneal macrophages stimulated with TNF
in vivo, or BMDM stimulated with TNF in vitro, have an abnormal
transcriptional response which implicates Mecp2 as a key regu-
lator of inflammatory gene programs in macrophages. Of note,
TNF is a widely used cytokine with important functions in both
the CNS and PNS in the context of normal, non-inflammatory
function and development (Stellwagen and Malenka, 2006;
Wheeler et al., 2014). Based on what we have demonstrated in
macrophages, it is possible that TNF signaling in neurons is
also impaired in the absence of Mecp2, potentially contributing
to abnormal neuronal function and/or development in Rett syn-
drome. This possible cascade will be evaluated in future studies.
These results provide evidence that Mecp2 plays an important
role in the epigenetic regulation of macrophage responses and
implicate macrophages as therapeutic targets in Rett syndrome.
Importantly, we found that three stimuli (glucocorticoids,
hypoxia, and inflammation) were transcriptionally dysfunctional
in the absence of Mecp2, associating Mecp2 as a widely used
epigenetic regulator in macrophages. Given that Mecp2 regu-
lates multiple response pathways in macrophages, it is impor-
tant to note that the exact effects of Mecp2-deficiency in
macrophages in the context of a severe whole-body disease
such as Rett syndrome becomes extremely difficult to predict,
especially when one considers the variation in location, context,
and functions of macrophages throughout the body. Thus, future
studies should consider Mecp2 as an important player in
the transcriptional regulation of macrophage responses and
endeavor to understand the role of Mecp2 in the many unique
macrophage populations.
EXPERIMENTAL PROCEDURES
Additional experimental procedures can be found in the Supplemental
Information.
Animals
Male and female C57Bl/6J, B6.129P2(C)-Mecp2tm1.1Bird/J, B6.129P2-
Mecp2tm2Bird/J, and B6.129P-Cx3cr1tm1Litt/J mice were purchased from Jack-
son Laboratories and/or bred in house using stock obtained from Jackson
Laboratories. Cx3cr1creER mice were kindly provided by S. Jung (WeizmannImmunity 42, 679–691, April 21, 2015 ª2015 Elsevier Inc. 689
Institute of Science) and were maintained in our laboratory on C57Bl/6J back-
ground. All animals were housed in temperature and humidity controlled
rooms, and maintained on a 12 hr/12 hr light/dark cycle (lights on at 7:00).
All strains were kept in identical housing conditions. Mice were scored for pa-
thology based on a 3-point scale across four categories: hind-limb-clasping,
tremors, gait, and general appearance. For each category, 3 = wild-type, 2 =
mid-phenotypic, and 1 = late-phenotypic. Mice that scored in-between 3
and 2 were considered early/pre-phenotypic. Approximate ages for pre-
phenotypic mice were 4–5 weeks, and for late-phenotypic 8–12 weeks; how-
ever, all experiments were performed and labeled based on actual phenotype
of themice. All procedures complied with regulations of the Institutional Animal
Care and Use Committee at The University of Virginia.
Tamoxifen Treatment
Tamoxifen (Sigma T5648) was solubilized in corn oil (Sigma) at 10 mg/ml. Mice
were injected three times, subcutaneously, between the shoulder blades, at
48 hr intervals at a dose of 100 mg/kg. For tamoxifen feeding, mice were
placed on tamoxifen diet TD.130856 (Harlan Laboratories) for up to 3 months
before analysis, while controls were left on normal mouse chow (Harlan
Laboratories).
RNA-Seq Analysis
Total RNA was extracted using the RNeasy mini kit (QIAGEN). RNA-seq was
performed by Hudson Alpha Genomic Services Laboratory. Statistical analysis
and data post-processing were performed with in-house developed functions
in Matlab (Litvak et al., 2009; Litvak et al., 2012). For transcriptome analysis of
wild-type and Mecp2-null microglia and peritoneal macrophages, genes were
selected for inclusion on the basis of filtering for minimum log2 expression
intensity (>4).
Gene Set Enrichment Analysis
Gene set enrichment analysis (GSEA) is an analytical tool for relating
differentially regulated genes to transcriptional signatures and molecular
pathways associated with known biological functions (Subramanian et al.,
2005). The statistical significance of the enrichment of known transcriptional
signatures in a ranked list of genes was determined as described (Subrama-
nian et al., 2005). To assess the phenotypic association with Mecp2 defi-
ciency, we used the list of genes that was ranked according to differential
gene expression in Mecp2-null and wild-type microglia. We used 4,722
gene sets from the Molecular Signature Database C2 version 4.0 and 32
custom gene sets including hypoxia and glucocorticoid-stimulated gene
sets (Table S1).
Quantitative Chromatin Immunoprecipitation Analysis
ForChIPanalysis, formalin-fixedcellswere sonicatedandprocessed for immu-
noprecipitation essentially as described (Ning et al., 2011). In brief, 1.5 3 107
BMMs were cross-linked for 10 min in 1% paraformaldehyde, washed, and
lysed. Chromatin was sheared by sonication (5 cycles 3 60 sec each cycle at
30% maximum potency) to fragments of approximately 150 bp. For Mecp2
ChIP, the sheared chromatin was incubated with anti-Mecp2 antibodies
(ABE171) (Millipore), and then immunoprecipitated using anti-rabbit immuno-
globulin G (IgG) Dynabeads (Invitrogen) pre-conjugated with anti-Chicken IgY
antibodies (ab6877) (Abcam), washed, and eluted. For acH4 ChIP, the sheared
chromatin was incubated with anti-rabbit IgG Dynabeads (Invitrogen) pre-con-
jugated with antibodies acH4 (06-598) (Upstate) or Isotype control IgG1 (BD
Pharmigen), washed, and eluted. Eluted chromatin was reverse-cross-linked,
and DNA was purified using phenol/chloroform/isoamyl extraction.
For quantitative ChIP, immunoprecipitated DNA samples were amplified
with Fkbp5-promoter-specific primers (Forward: TGCACTGCCTATGCAAA
TGA and Reverse: AGCTTCCTCCATCCCTCTT) using TaqMan quantitative
PCR analysis. PCR samples from IgY-ChIPs served as a negative control.
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